Pancreatic Cancer Research

ResearcherTongji UniversityActive in the last 2 years

Jun Gao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0007-1487-2861; OpenAlex author ID A5078734134. Sources: OpenAlex.

Their work

Papers
26 (first author 6, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
88
Papers, trials and grants by year

2011: 5 papers · 2012: 2 papers · 2013: 6 papers · 2014: 1 paper · 2015: 3 papers · 2016: 3 papers · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 26

  1. miR-301a-mediated crosstalk between the Hedgehog and HIPPO/YAP signaling pathways promotes pancreatic cancer. Last author DOI 10.1080/15384047.2025.2457761↗
  2. Positive Crosstalk Between Hedgehog and NF-κB Pathways Is Dependent on KRAS Mutation in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.652283↗
  3. MicroRNA-132 Plays an Independent Prognostic Role in Pancreatic Ductal Adenocarcinoma and Acts as a Tumor Suppressor. Co-author DOI 10.1177/1533033818824314↗
  4. Significance of IL28RA in diagnosis of early pancreatic cancer and its regulation to pancreatic cancer cells by JAK/STAT signaling pathway - effects of IL28RA … Co-author DOI 10.26355/eurrev_201911_19550↗
  5. Novel three‑lncRNA signature predicts survival in patients with pancreatic cancer. Co-author DOI 10.3892/or.2018.6761↗
  6. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2174/1566524018666180308115705↗
  7. Bulk pancreatic cancer cells can convert into cancer stem cells(CSCs) in vitro and 2 compounds can target these CSCs. Co-author DOI 10.1080/15384101.2015.1127471↗
  8. Identification of a novel alternative splicing transcript variant of the suppressor of fused: Relationship with lymph node metastasis in pancreatic ductal aden… First author DOI 10.3892/ijo.2016.3753↗
  9. Hedgehog Signaling Non-Canonical Activated by Pro-Inflammatory Cytokines in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.15786↗
  10. Apoptosis and anergy of T cell induced by pancreatic stellate cells-derived galectin-1 in pancreatic cancer. First author DOI 10.1007/s13277-015-3233-5↗
  11. GSH2 promoter methylation in pancreatic cancer analyzed by quantitative methylation-specific polymerase chain reaction. Co-author DOI 10.3892/ol.2015.3241↗
  12. MicroRNA-222 Controls Human Pancreatic Cancer Cell Line Capan-2 Proliferation by P57 Targeting. Co-author DOI 10.7150/jca.12546↗
  13. Pancreatic satellite cells derived galectin-1 increase the progression and less survival of pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0090476↗
  14. Adenovirus vector-mediated Gli1 siRNA induces growth inhibition and apoptosis in human pancreatic cancer with Smo-dependent or Smo-independent Hh pathway activ… First author DOI 10.1016/j.canlet.2013.06.010↗
  15. Aberrant microRNAs expression patterns in pancreatic cancer and their clinical translation. Co-author DOI 10.1089/cbr.2012.1389↗
  16. Identification of common variants in BRCA2 and MAP2K4 for susceptibility to sporadic pancreatic cancer. Co-author DOI 10.1093/carcin/bgt004↗
  17. Aberrant expression miR-196a is associated with abnormal apoptosis, invasion, and proliferation of pancreatic cancer cells. Co-author DOI 10.1097/mpa.0b013e3182962acb↗
  18. Lamin B1 is a novel therapeutic target of betulinic acid in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-12-3630↗
  19. Aberrant DNA methyltransferase expression in pancreatic ductal adenocarcinoma development and progression. Co-author DOI 10.1186/1756-9966-32-86↗
  20. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. First author DOI 10.1002/ijc.26422↗
  21. Hepatitis B virus status and risk of pancreatic ductal adenocarcinoma: a case-control study from China. Co-author DOI 10.1097/mpa.0b013e31822ca176↗
  22. Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Co-author DOI 10.1007/s10620-010-1285-3↗
  23. The neuronal pentraxin II gene (NPTX2) inhibit proliferation and invasion of pancreatic cancer cells in vitro. First author DOI 10.1007/s11033-010-0632-y↗
  24. Detection of KRAS gene mutations in endoscopic ultrasound-guided fine-needle aspiration biopsy for improving pancreatic cancer diagnosis. First author DOI 10.1038/ajg.2011.281↗
  25. Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. Co-author DOI 10.1038/ng.1020↗
  26. Continuous and low-energy 125I seed irradiation changes DNA methyltransferases expression patterns and inhibits pancreatic cancer tumor growth. Co-author DOI 10.1186/1756-9966-30-35↗

Closest collaborators

The 25 strongest of 88 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuqiong Wang · 5 shared papers, 2015–2025 · strength 0.56
  2. Yan-fang Gong · 9 shared papers, 2011–2025 · strength 0.51
  3. Hongyu Wu · 4 shared papers, 2013–2025 · strength 0.45
  4. Xiangyu Kong · 6 shared papers, 2011–2021 · strength 0.30
  5. Yiqi Du · 8 shared papers, 2011–2016 · strength 0.29
  6. Zhaoshen Li · 5 shared papers, 2013–2019 · strength 0.27
  7. Kaixuan Wang · 4 shared papers, 2012–2021 · strength 0.26
  8. Bing Qi · 1 shared paper, 2025 · strength 0.25
  9. Zhao‐Shen Li · 4 shared papers, 2013–2016 · strength 0.20
  10. Hongyu Wu · 4 shared papers, 2011–2016 · strength 0.15
  11. Zhengxiang Zhong · 2 shared papers, 2017–2018 · strength 0.15
  12. Hongwei Xu · 1 shared paper, 2021 · strength 0.12
  13. W-W Zeng · 1 shared paper, 2019 · strength 0.11
  14. Lily Yang · 1 shared paper, 2019 · strength 0.11
  15. Qing Xu · 1 shared paper, 2016 · strength 0.10
  16. Zhao‐Shen Li · 1 shared paper, 2016 · strength 0.10
  17. Yiqi Du · 1 shared paper, 2019 · strength 0.10
  18. Yan Chen · 1 shared paper, 2019 · strength 0.10
  19. Huiyun Zhu · 1 shared paper, 2019 · strength 0.10
  20. Zhaoshen Li · 3 shared papers, 2011–2013 · strength 0.09
  21. Shu-De Li · 2 shared papers, 2013–2016 · strength 0.09
  22. Minghao Liu · 2 shared papers, 2013 · strength 0.09
  23. Haojie Huang · 2 shared papers, 2011–2015 · strength 0.09
  24. Qiwen Ben · 2 shared papers, 2012–2016 · strength 0.08
  25. Dong Tang · 2 shared papers, 2014–2015 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.